Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Document Type
Journal Article
Publication Date
11-1-2018
Journal
PLoS medicine / Public Library of Science
Volume
15
Issue
11
DOI
10.1371/journal.pmed.1002690
APA Citation
Landovitz, R., Li, S., Grinsztejn, B., Dawood, H., Liu, A., Magnus, M., Hosseinipour, M., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M., Hendrix, C., Eshleman, S., Zhang, Y., Tolley, E., Sugarman, J., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A., Margolis, D., Spreen, W., Cohen, M., McCauley, M., & Eron, J. (2018). Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.. PLoS medicine / Public Library of Science, 15 (11). http://dx.doi.org/10.1371/journal.pmed.1002690
Peer Reviewed
1
Open Access
1